Acarix and CADScor®System has won the Global Health & Pharma technology awards 2021 as Most Innovative Coronary Artery Disease Analytical Device 2021.

We are very proud as winning this award is the recognition and testament of the CADScor®System technological strength and uniqueness in the field of coronary artery disease.

The technology embedded in the CADScor®System integrates artificial intelligence and ultrasensitive phonocardiography into an intelligent AI-powered diagnostic aid. With the CADScor®System, Acarix leads the paradigm shift to AI-powered assessment of CAD.

The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor®System calculates a patient-specific CAD-score non-invasively in less than 10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence).

About the Global Health & Pharma technology awards:
The GHP The awards celebrate businesses and professionals who have made exceptional contributions and innovations in the medical technology industry. Over the years, the adoption of technology in the healthcare industry has led to greater prevention of illness, injury or other conditions, diagnosis, monitoring, treatment and care of patients. Across all sectors, the healthcare sector benefits most from technology because it improves quality of life and has saved many lives.

In addition, in recent years, there have been several technological advances in the health and medical fields, for example, 3D printing, artificial organs, robotic surgery, health wearables, virtual reality (VR), telehealth, etc.

About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix.

For more information, please visit www.acarix.com.